Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
This article was originally published in The Pink Sheet Daily
Japanese drug maker takes a stronger position in oncology, expands U.S. presence.
You may also be interested in...
Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.
Onyx Pharmaceuticals is working to execute on two launches and produce late-stage data that will enable it to add more indications to its growing roster of marketed drugs. If it succeeds, it could eventually rival competitor Celgene as one of the few biotechs to move from a small cap into the big cap ranks, but any stumbles could slow or eliminate Onyx’s evolution.